AADi, LLC, - also dba as AADI Biosciences - is a clinical stage biopharmaceutical company structured around in-house invented, lead product TARZIFYX⢠- sirolimus albumin-bound nanoparticles for injectable suspension, ABI-009 -- mTOR inhibitor complexed with human albumin that has significantly higher tumor accumulation and improved efficacy over other mTOR inhibitors in preclinical models. With mTOR as a therapeutic target well recognized in oncology, Aadi is focused on developing the full potential of albumin-bound sirolimus in therapeutic areas and diseases that are driven by mTOR activation and where the mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety or effective targeting to the disease site. These indications include oncology, cardiovascular, CNS, mitochondrial disease and diseases of ageing.
